COVID-19: 'Increased risk' of rare nerve disorder after J&J vaccine

US officials identify 100 preliminary reports of Guillain-Barre Syndrome from 12.5m doses

Last updated:
1 MIN READ
Johnson & Johnson vaccine J&J
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020.
Reuters

Washington: The US Food and Drug Administration on Monday updated its warning labels for the Johnson & Johnson COVID-19 vaccine to include information about an observed “increased risk” of a rare neurological disorder.

Based on analysis of a federal vaccine safety monitoring system, officials have identified 100 preliminary reports of Guillain-Barre Syndrome after approximately 12.5 million doses administered, people familiar with the matter said.

Of these reports, 95 of them were serious and required hospitalization. There was one reported death.

Sign up for the Daily Briefing

Get the latest news and updates straight to your inbox